Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Carlyle (CGABL) Cash & Equivalents (2016 - 2025)

Carlyle has reported Cash & Equivalents over the past 15 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $2.0 billion for Q4 2025, up 55.62% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 55.62% YoY), and the annual figure for FY2025 was $2.0 billion, up 55.62%.
  • Cash & Equivalents for Q4 2025 was $2.0 billion at Carlyle, down from $2.2 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for CGABL hit a ceiling of $2.5 billion in Q4 2021 and a floor of $870.3 million in Q2 2023.
  • Median Cash & Equivalents over the past 5 years was $1.3 billion (2022), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Cash & Equivalents: surged 186.06% in 2021 and later crashed 44.9% in 2022.
  • Carlyle's Cash & Equivalents stood at $2.5 billion in 2021, then plummeted by 44.9% to $1.4 billion in 2022, then increased by 5.85% to $1.4 billion in 2023, then decreased by 12.1% to $1.3 billion in 2024, then soared by 55.62% to $2.0 billion in 2025.
  • The last three reported values for Cash & Equivalents were $2.0 billion (Q4 2025), $2.2 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.